Home › Endometrial Cancer › Rhode Island › Providence
Endometrial Cancer clinical trials in Providence, RI
15 studies for Endometrial Cancer are looking for participants at sites in and around Providence (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RecruitingPhase 3
- Women and Infants Hospital, Providence
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RecruitingPhase 2
- Women and Infants Hospital, Providence
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RecruitingPhase 2
- Women and Infants Hospital, Providence
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecruitingPhase 3
- Women & Infants Hospital ( Site 5003), Providence
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RecruitingPhase 1
- Women & Infants Hospital of Rhode Island, Providence
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RecruitingPhase 1
- Women and Infants Hospital, Providence
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, Providence
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RecruitingPhase 2
- Women & Infants Hospital, Providence
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RecruitingPhase 1/2
- Research Site, Providence
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- Women and Infants Hospital of Rhode Island, Providence
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
RecruitingPhase 2
- Women & Infants Hospital, Providence
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RecruitingPhase 1/2
- Women & Infants Hospital, Providence
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Providence
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY53 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN37 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- San Antonio, TX27 studies
- Columbus, OH26 studies
- Chicago, IL26 studies
- Queens, NY26 studies
Other studies in Providence
- Ovarian Cancer15 studies
- Obesity14 studies
- Cancer (all types)13 studies
- Crohn's Disease12 studies
- Non-Small Cell Lung Cancer12 studies
- Breast Cancer11 studies
- Ulcerative Colitis11 studies
- Acute Myeloid Leukemia10 studies
- Overweight9 studies
- Metastatic Cancer9 studies
- Alcohol Use Disorder (AUD)8 studies
- Alzheimer's Disease8 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.